Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   ARCHIVES OF IRANIAN MEDICINE   January 2019 , Volume 22 , Number 1; Page(s) 7 To 10.
 
Paper: 

Generation of CD19-Targeted Chimeric Antigen Receptor T Cells

 
 
Author(s):  Kiani Jafar, NADERI MAHMOOD, Torabi Rahvar Monireh, RANJBAR AZAM, Aghayan Hamid Reza, Janzamin Ehsan, Ahmadbeigi Naser*
 
* Cell Based Therapies Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
 
Abstract: 
Background: Current advancements in the field of chimeric antigen receptor (CAR) therapy, particularly U. S. FDA approval of Kymriah and Yescarta, heralds a new era of cancer treatment. This rapid progress in technology has urged more countries and institutions to keep pace with the fast-growing and developing technology of producing CAR T cell-based therapies in the race to develop new cancer-targeting drugs. Hence, for stepping in line with global advances and to pave the way for subsequent preclinical and clinical studies, we have established a development protocol for a cancer-targeting CAR T cell; we have chosen CD19 CAR T cell as a well-defined model to set-up T cell expansion, activation, and viral transduction as the prerequisites for diverse CAR T cell therapies. Methods: T cells from peripheral blood mononuclear cells (PBMCs) were activated and expanded. CD19 CAR lentiviral particles were produced in the Lenti-X™ 293T Cell Line using PolyFect Transfection Reagent. Results: Activation protocol resulted in (65 ± 4%; P = 0. 046) increase in the rate of activated T cells 24 hours after the initiation of the procedure. The expansion methodology resulted in a high purity of the T cell population (96 ± 3%) in the pool of PBMCs within 14 days of the procedure. Finally, 35 ± 6% of T cells were transduced with CD19 lentivirus with MOI of 3. Conclusion: Collectively, the results of this study prove that we have successfully overcome the first hurdle on the road to reach CAR T cell technology which is the prerequisite for developing preclinical and clinical phases of CAR therapy in settings with basic resources.
 
Keyword(s): B-cell malignancies,CAR T cell,CD19,Chimeric antigen receptor
 
 
References: 
 
Click to Cite.
APA: Copy

Kiani, J., & NADERI, M., & Torabi Rahvar, M., & RANJBAR, A., & AGHAYAN, H., & Janzamin, E., & AHMADBEIGI, N. (2019). Generation of CD19-Targeted Chimeric Antigen Receptor T Cells. ARCHIVES OF IRANIAN MEDICINE, 22(1), 7-10. https://www.sid.ir/en/journal/ViewPaper.aspx?id=664354



Vancouver: Copy

Kiani Jafar, NADERI MAHMOOD, Torabi Rahvar Monireh, RANJBAR AZAM, AGHAYAN HAMID REZA, Janzamin Ehsan, AHMADBEIGI NASER. Generation of CD19-Targeted Chimeric Antigen Receptor T Cells. ARCHIVES OF IRANIAN MEDICINE. 2019 [cited 2021May12];22(1):7-10. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=664354



IEEE: Copy

Kiani, J., NADERI, M., Torabi Rahvar, M., RANJBAR, A., AGHAYAN, H., Janzamin, E., AHMADBEIGI, N., 2019. Generation of CD19-Targeted Chimeric Antigen Receptor T Cells. ARCHIVES OF IRANIAN MEDICINE, [online] 22(1), pp.7-10. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=664354.



 
  pdf-File
Yearly Visit 62
 
Latest on Blog
Enter SID Blog